================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

          (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 150(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                  FOR THE QUARTERLY PERIOD ENDING: May 31, 2007

          ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

              For the transition period from _________ to _________

                           COMMISSION FILE NO. 1-11047

                           SPARTA SURGICAL CORPORATION
           (Name of Small Business Issuer as specified in its Charter)


                  Delaware                            22-2870438
            (State Incorporated)             (I.R.S. Employer ID Number)

        5445 DTC Parkway, Suite 520
           Greenwood Village, CO                        80111
  (Address of Principal Executive Offices)            (Zip Code)

                                  848-391-2893
                           (Issuer's Telephone Number)

Check whether the issuer (I) has filed all reports required to be filed by
Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days: Yes (X) No ( ).

           Securities registered pursuant to Section 12(b) of the Act:

                                                           Name of each exchange
Title of Class                                              on which registered

$0.002 Par Value Common Stock                                       None.
$4.00 Par Value Redeemable Convertible Preferred Stock              None.
$4.00 Par Value Series A Convertible Preferred Stock                None.





                                       1
<PAGE>
           Securities registered pursuant to Section 12 (g) of the Act

                          $0.002 Par Value Common Stock
              $4.00 Par Value Series A Convertible Preferred Stock
               $4.00 Par Value Series Convertible Preferred Stock

The Registrant had $3,129 in revenue for its most recent fiscal year.

As of May 31, 2007, 9,973,830 shares of Registrant's Common Stock, 82,533 shares
of Redeemable Convertible Preferred Stock, and 27,818 shares of Series A
Convertible Preferred Stock were outstanding.









                                       2
<PAGE>

                          SPARTA SURGICAL CORPORATION

                                   Form 10-QSB

                                      INDEX


Part I.      Financial Information

          Item 1.  Financial Statements (Unaudited)                           4

                   Balance Sheet
                   As of May 31, 2007
                   (Unaudited)                                                4

                   Statements of Operations
                   for the three months ended
                   May 31, 2007 and 2006
                   (Unaudited)                                                5

                   Statements of Cash Flows
                   for the three months ended
                   May 31, 2007 and 2006
                   (Unaudited)                                                6

          Item 2.  Management's Discussion and
                   Analysis of Financial Condition and
                   Results of Operations
                   (Unaudited)                                               13

          Item 3.  Controls and Procedures                                   17

Part II.  Other Information and Change in Securities

          Item 1.  Legal Proceedings                                         17

          Item 2.  Change in Securities                                      17

          Item 3.  Default upon Senior Securities                            18

          Item 4.  Submission of Matters to Vote of Security Holders         18

          Item 5.  Other Information                                         18

          Item 6.  Exhibits and Signatures                                   18





                                       3
<PAGE>

                           Sparta Surgical Corporation
                                  Balance Sheet
                                  May 31, 2007
                                   (unaudited)

ASSETS
         Accounts Receivable                                    $         9,907
                                                                ----------------

            TOTAL ASSESTS                                       $         9,907
                                                                ================



LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
    Accounts Payable                                            $        82,752
    Accrued Taxes Payable                                                95,512
    Accrued Interest for Notes Payable                                   92,599
    Notes Payable to Trust                                              198,718
    Notes Payable to Trust                                              181,568
    Notes Payable to Credit Facility                                     49,247
    Dividend Payable on Preferred Stock                                 135,225
                                                                ----------------

        TOTAL CURRENT LIABILITIES                                       835,621
                                                                ----------------


STOCKHOLDERS' EQUITY Preferred Stock:
    1992 Non-cumulative Convertible Redeemable
      Preferred Stock, 165,000 shares authorized,
      82,533 shares issued and outstanding.                             330,132
    Series A Cumulative Convertible Preferred Stock,
      30,000 shares authorized, 27,818 shares issued
      and outstanding.                                                  111,272
    Series AA Cumulative Convertible Preferred
      Stock, 875,000 Shares authorized, none issued
      and outstanding.                                                        -
    Common Stock, $0.002 par value, 25,000,000
      authorized and 9,973,830 outstanding                               15,467
    Additional Paid in Capital                                       14,486,197
    Accumulated Deficit                                             (15,768,782)
                                                                ----------------


        TOTAL STOCKHOLDERS' EQUITY                                     (825,714)
                                                                ----------------

        TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY              $         9,907
                                                                ================

See accompanying notes to financial statements




                                       4
<PAGE>

                          Sparta Surgical Corporation
                             Statement of Operations
                                   (unaudited)



                                                   For the Three Months Ended:
                                                May 31, 2007      May 31, 2006

Revenue                                       $         3,129   $             -
                                              ----------------------------------

Gross Profit                                            3,129                 -
                                              ----------------------------------

Selling, General and Administrative                     8,683             3,484
                                              ----------------------------------
Expenses

Loss from Operations                                   (5,554)           (3,484)
                                              ----------------------------------

Other Income (Expense):
     Interest Expense                                  (6,954)           (5,677)
     Gain on Extinguishment of Debt                         -                 -
                                              ----------------------------------

     Total Other Income (Expense)                      (6,954)           (5,677)
                                              ----------------------------------

     Net Loss                                         (12,508)           (9,161)

Cumulative Preferred Dividends                         (9,999)           (4,656)
                                              ----------------------------------

     Net Loss to Common Shareholders          $       (22,507)  $       (13,817)
                                              ==================================

     Weighted Average Shares                        9,973,830         9,973,830
                                              ==================================

Basic and Diluted Earning per Share
     Net Loss per share                       $          0.00   $          0.00
                                              ==================================

See accompanying notes to financial statement




                                       5
<PAGE>

                          Sparta Surgical Corporation
                            Statements of Cash Flows
                                   (unaudited)



                                                  For the Three Months Ended:

                                                May 31, 2007      May 31, 2006

Cash flows from operating activities
Net Loss                                      $       (22,507)          (13,817)
                                              ----------------------------------
Adjustments to reconcile operating loss
  to net cash used in operating activities:
    Preferred dividends                                 9,999             4,656
    Change in operating assets and
     liabilities:
       Accounts receivable                             (3,129)                -
       Accounts payable                                 7,240                 -
       Accrued expenses                                 6,954             5,678
                                              ----------------------------------

        Net cash used in operating
        activities                                     (1,443)           (3,483)
                                              ----------------------------------

Cash flows from financing activities
    Proceeds from note payable                          1,443             3,483
                                              ----------------------------------
Net cash provided by financing activities               1,443             3,483
                                              ----------------------------------

Net change in cash and cash equivalents                     -                 -

Cash and cash equivalents at
     beginning of period                                    -                 -
                                              ----------------------------------

Cash and cash equivalent at
     end of period                            $             -   $             -
                                              ==================================


See accompanying notes to financial statements




                                       6
<PAGE>

                          Sparta Surgical Corporation

                        Notes to the Financial Statement


Note 1. Business and Summary of Significant Accounting Policies

Sparta Surgical Corporation, (the "Company") was incorporated in Delaware on
March 23, 1984. The Company was engaged in the research, development,
manufacturing and marketing of surgical and electrotherapy products for the
worldwide healthcare industry. In May 2002, the Company divested substantially
all of its assets and ceased operations. As a result, the Company retained no
assets after ceasing operations, and has performed only administrative duties as
a transitory, or shell, corporation. Since May 2002, the Company has sought to
acquire a new business opportunity. In September 2006, the Company was appointed
as an exclusive independent sales representative to market certain surgical,
medical devices and accessories and thereby re-entered the medical device
industry. In addition, the Company's affiliate was appointed to market
exclusively certain electrotherapy product lines. Accordingly, the Company and
its affiliate intends to utilize this new relationship to form a basis for its
future activities and attempt to produce income. However, there can be no
assurance that the Company will succeed with this new business strategy and or
produce any future income.

In June 2002 and March 2004, the Company issued to LKDTBJP Living Trust, (the
"Living Trust"), various Convertible Secured Promissory Notes, (the "Convertible
Notes") in the amount of $380,286 for assuming certain of the Company's debt and
notes payable. The Convertible Notes, both principal and accrued interest, were
due on June 15, 2006 and May 17, 2006, at 6% interest per annum. On May 12,
2006, Living Trust agreed to extend payments on both principal and accrued
interest under the Convertible Notes until February 28, 2008. At the option of
the Living Trust, the Convertible Notes are convertible at any time into
15,000,000 shares of the Company's Common Stock.

In September 2005, the Company entered into a Revolving Credit Facility
Agreement (the "Agreement"), by and between Gary A. Agron (the "Agron") and
Living Trust (collectively the "Lender"). This Agreement allows the Company to
borrow up to $100,000 with interest charged at 6.0% per annum, and both
principal and accrued interest is due on February 28, 2008. The Company further
agreed not to issue any additional equity or any other type of security without
the written consent of the Lender. In consideration of the Lender providing a
revolving credit, the Company has agreed to issue each of Agron and Living Trust
46,269,023 shares for a total of 92,538,046 shares of the Company's Common Stock
(the "Loan Shares"). On October 6, 2006, subject to the confirmation of the
Company's Plan of Reorganization, the Agreement was amended to reduce the number
of shares to 10,000,000 to the lender. The Company has valued these shares at
approximately $1,000.


                                       7
<PAGE>


The Company further acknowledged that it currently does not have sufficient
shares of common stock authorized for the issuance of the Loan Shares, however,
the Company shall take all reasonable actions necessary, including the holding
of a shareholder meeting to amend the Company's Certificate of Incorporation to
authorize shares of the Company's common stock so that Loan Shares may be
issued.

In September 2005, the Company did not have sufficient funds to pay Allan J.
Korn, its President, for his past services. Therefore the Company authorized
issuance of 5,443,415 shares of its Common Stock valued at $544.34 to Mr. Korn,
who has acted as the Company's sole officer and director without compensation
for the past four years. On October 6, 2006, subject to the confirmation of the
Company's Plan of Reorganization, the Company and Mr. Korn agreed to reduce the
number of shares to 50,000. In November 2006, the Company's affiliate did not
have sufficient funds to pay Mr. Korn for assuming the position of President,
sole officer and director. Therefore, the affiliate agreed to authorize to issue
25,000 shares of its Common Stock to Mr. Korn.

In November 2006, the Company's affiliate entered into a $100,000 Revolving
Credit Facility Agreement by and between the Lender. The terms and conditions
under this Credit Facility are the same as the Company's with the exception that
in consideration of the Lender providing the credit facility, the affiliate
authorized to issue 850,000 shares of its common stock to the Lender.


Significant Accounting Policies

There have been no significant changes in Company's significant accounting
policies during the three months ended May 31, 2007 as compared to what was
previously disclosed.

Income Taxes

No provision for federal and state income taxes has been recorded as the Company
has incurred net operating losses through May 31, 2007. The Company believes
sufficient uncertainty exists regarding the realizability of the deferred tax
assets such that a full valuation allowance is required, leaving a net deferred
tax asset of $-0-. The Company also has net operating loss carryforwards for tax
reporting periods. The Company retained no assets after ceasing operations on
May 2, 2002, and has performed only administrative duties as a transitory, or
shell, corporation. The Company seeks to merge with an operating company and
does not believe net operating loss carryforwards will be available to offset
future taxable income after such merger.

Basic and Diluted Earnings Per Common Shares

In accordance with Financial Accounting Standards Boards ("FASB") No. 128, basic
earnings per share is computed by dividing net income by the number of weighted
average common shares outstanding during the year. Diluted earnings per share is
computed by dividing net income by the number of weighted average common shares


                                       8
<PAGE>

outstanding during the year. For the three months ended May 31, 2007 and 2006
there is no difference between the basic and diluted loss per share, as there
were no dilutive stock options.


                                               Three Months       Three Months
                                               Ended May 31,      Ended May 31,
                                                   2007              2006

Numerator:
Net Loss applicable to common stockholders    $       (22,507)  $       (13,817)

Denominator
Weighted average shares outstanding during
  the period                                        9,973,830         9,973,830

Basic and diluted loss per common share                 (0.00)            (0.00)

Revenue Recognition

The Company recognizes revenue when commissions are earned under the Exclusive
Sales Representative Agreement. Provision for allowances, and other adjustments
are provided for in the same period the related revenues are recorded.

Long-Lived Assets

The Company reviews its long-lived assets for impairment whenever events or
changes in circumstances indicate that the carrying amount of the asset may not
be recovered. The Company looks primarily to the undiscounted future cash flows
in its assessment of whether or not long-lived assets have been impaired.

Recently Issued Accounting Pronouncements

In September 2006, the Securities and Exchange Commission ("SEC") released Staff
Accounting Bulletin No. 108, "Considering the Effects of Prior Year
Misstatements when Quantifying Misstatements in Current Year Financial
Statements," ("SAB No. 108"). SAB No. 108, which is effective for fiscal years
ending after November 15, 2006, provides guidance on how the effects of prior
year uncorrected misstatements, previously deemed to be immaterial, must be
considered and adjusted during the current year. The Company does not anticipate
that the adoption of SAB 108 will have a material effect on its statements of
operations in future periods.



                                       9
<PAGE>

Use of Estimates

The preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America require management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosures of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expense during the
reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments

The fair value of accounts payable and accrued expenses approximates carrying
value due to the short-term nature of such instruments. The fair value of debt
obligations with related parties and individuals is not determinable due to the
terms of the debt and there is no comparable market for such debt.

Concentration of Credit Risk

There are no financial statements that potentially subject the Company to
significant concentrations of credit risk.

Note 2 - Going Concern

The accompanying financial statements have been prepared on a going concern
basis which contemplates the realization of assets and liquidation of
liabilities in the ordinary course of business.

During 2001 and 2002, the Company entered into and completed an agreement to
sell all of its operating assets.

In September 2005, the Company entered into a Revolving Credit Facility. This
Revolving Credit Facility allows the Company to borrow up to $100,000 with
interest charged at 6.0% per annum.

In November 2006, the Company and its affiliate filed its Plan of Reorganization
and Accompanying Disclosure Statement for relief under Chapter 11 in the United
States Bankruptcy Court for the District of Colorado.



                                       10
<PAGE>

Note 3- Related Party Transactions

Office Space

The Company's uses office space located in its Chief Executive Officer's office.
The Company estimates the fair value of these services to be $1,200 per year and
these amounts have not been recorded in the financial statements.

Amounts Due to Related Parties

As of May 31, 2007, the Company had amounts due to the Lender in the amount of
$49,247 in connection with the $100,000 Revolving Credit Facility Agreement
dated September 9, 2005.

As of May 31, 2007, in connection with the Company's Convertible Notes, the
Company had amounts due of $380,286, including accrued interest of $92,599, a
total aggregate amount of $472,885 to Living Trust.

Current Notes payable consists of the following:

Credit Facility dated 9/9/05 for $100,000
at 6% due February, 2008                                        $        49,247

6% note due in February 2008, collateralized
by substantially all assets of the Company
and convertible into 7,500,000 shares of the
Company's Common Stock                                                  198,718

6% note due in February 2008, collateralized
by substantially all assets of the Company
and convertible into 7,500,000 shares of the
Company's Common Stock                                                  181,568

                                                                ----------------

                                                                $       429,533
                                                                ================

Note 4 - Stockholders' Equity

Preferred Stock

The authorized Preferred Stock of the Company consists of 2,000,000 shares,
$4.00 par value. The Preferred Stock may be issued in series from time to time
with such designations, rights, preferences, and limitations as the Board of


                                       11
<PAGE>

Directors of the Company may determine by resolution. The rights, preferences
and limitations of separate series of Preferred Stock may differ with respect to
such matters as may be determined by the Board of Directors, including without
limitation, the rate of dividends, method and nature of payment of dividends,
terms of redemption, amounts payable on liquidation, sinking fund provisions,
conversion rights and voting rights.

1992 Preferred Stock

The Company has authorized 165,000 shares of Non-Cumulative Convertible
Preferred Stock (the "1992 Preferred Stock"). The holders of the 1992 Preferred
Stock shall be entitled to receive non-cumulative dividends, at the rate of 10%
per annum or $0.40 per share, for each year that the Company has net income
after taxes. The holders of 1992 Preferred Stock are entitled to vote on matters
upon which holders of the common stock have the right to vote, and shall be
entitled to the number of votes equal to the number of full shares of common
stock into which the shares of 1992 Preferred Stock could be converted. Each
share of 1992 Preferred Stock is convertible at the option of the holder into
one third of one share of common stock. Each preferred share is subject to
redemption at the Company's option at $4.00 per share under certain conditions.
The liquidation preference for the 1992 Preferred Stock is $4.00 per share.

Series A Preferred Stock

The Company has authorized 30,000 shares of Series A Convertible Redeemable
Preferred Stock (the "Series A Preferred Stock"). The holders of the Series A
Preferred Stock receive cumulative dividends at the quarterly rate of $0.375 per
share. The holders of Series A Preferred Stock have no voting rights except as
to matters affecting the rights of preferred stockholders or as required by law.
In connection with any such vote, each outstanding share of Series A Preferred
Stock has one vote. The Series A Preferred Stock is redeemable at the Company's
option, for cash at $10.00 per share plus any accrued and unpaid dividends. The
Series A Preferred Stock is $10.00 per share. The 1992 preferred Stock carries
liquidation rights senior to the Series A Preferred Stock.

Series AA Preferred Stock

The Company has authorized 875,000 shares of Series AA Convertible Redeemable
Preferred Stock (the "Series AA Preferred Stock"). The holders of the Series AA
Preferred Stock receive cumulative dividends at the annual rate of $0.28 per
share, payable semi-annually. The holders of the Series AA Preferred Stock have
no voting rights except as to matters affecting the rights of preferred
stockholders or as required by law. In connection with any such vote, each
outstanding share of Series AA Preferred Stock has one vote. The Series AA
Preferred Stock was convertible at any time through February 10, 2001 into


                                       12
<PAGE>

shares of common stock at a rate of 9 shares of common stock for each two shares
of Series AA Preferred Stock. The Series AA Preferred Stock will automatically
be converted into common stock at this rate in the event that the daily average
bid and ask price of common stock average $3.00 per share or more over a thirty
consecutive day period through February 10, 2001. At any time subsequent to
February 10, 2001, each two shares of Series AA Preferred Stock are redeemable
at the Company's option, for cash at $10.00 or $8.00 plus any accrued and unpaid
dividends in the event that the daily average bid and ask price of the common
stock average at least $2.00 per share or $3.00 per share, respectively, over a
thirty consecutive day period. The liquidation preference for the Series AA
Preferred Stock is $4.00 per share. The 1992 Preferred Stock and Series A
Preferred Stock carry liquidation rights senior to the Series AA Preferred
Stock.

As of May 31, 2007, the Company has accrued $135,225 for cumulative preferred
dividends.

Note 5 - Stock Options and Warrants

The 1987 Stock Option Plan (the "Plan") provided for the grant of both incentive
stock options and non-qualified stock options. A total of 250,000 shares of
common stock have been reserved for issuance under the Plan. In April 2000, the
Company extended the 1987 Stock Option Plan for an additional ten-year period,
until October 1, 2007. The Plan expired on October 1, 2007. As of May 31, 2007,
there are no outstanding Stock Options and Warrants issued.

Item 2.              MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS

We are a non-operating public company with no current revenues as we divested
substantially all of our assets and ceased operations in May 2002. In recent
years we have experienced losses from operations and continue to suffer from a
deficiency in available working capital. Except for the historical information
contained herein the matters set forth in this report are forward-looking
statements within the meaning of "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements are
subject to risks and uncertainties that may cause actual results to differ
materially. These risks are detailed from time to time in our periodic reports
filed with the Securities and Exchange Commission, including our Annual Report
on Form 10- KSB, Quarterly Reports on Form 10-QSB and other periodic filings.
These forward-looking statements speak only as of the date hereof. We disclaim
any intent or obligation to update these forward-looking statements.



                                       13
<PAGE>

These statements relate to future events in future financial performance and
involve known and unknown risks, uncertainties and other factor's that may cause
our or our industry's actual results, performance or achievements to be
materially different from these expressed or implied by any forward-looking
statements. All of these matters are difficult or impossible to predict
accurately and may be beyond our control. Although we believe that the
assumptions underlying our forward-looking statements are reasonable, any of the
assumptions could be inaccurate, therefore, there can be no assurance that the
forward-looking statements included in this Form 10-QSB will prove to be
accurate. The following discussions should be read in conjunction with the
unaudited Financial Statements and notes thereto, appearing elsewhere herein.

Risk Factors Affecting Future Operating Results

The following important factors, among others, could cause actual results to
differ materially from those contained in the forward-looking statements in this
Form 10-QSB, or presented elsewhere by management from time to time. We wish to
caution stockholders and investors that the following important factors, among
others, in some cases have affected, and in the future could affect our actual
results and could cause our actual results to differ materially, from those
expressed in any forward-looking statements made by us. These statements under
this caption are intended to serve as cautionary statements within the scope of
the Private Securities Litigation Reform Act of 1995. The following information
is not intended to limit in any way the characterization of other statements or
information under other caption as cautionary statements for such purpose. These
factors could have a material adverse effect on our non-operating business,
operating results and financial condition. Our results of operations vary
significantly from year to year and from quarter to quarter. We have incurred
net losses in prior years and can't assure future profitability. At May 31,
2007, our accumulated deficit was approximately $15,768,782.

The following are important factors that could cause actual results to differ
materially from those anticipated in any forward-looking statements made by or
on behalf of us.

We have incurred significant operating losses and will not be profitable in the
future as the Company has experienced circumstances which raise substantial
doubt about its ability to continue as a going concern.

We have discontinued all of our operations since May 2002, as we divested
substantially of our operating assets. We have incurred approximately
$15,768,782 in cumulative net losses from inception.



                                       14
<PAGE>

There is no significant trading market for our common stock.

Our common stock is not eligible for trading on any national or regional
exchange as we were delisted from the OTC Bulletin Board on July 2001. Our
common stock has no trading activity on the non NASDAQ Other OTC (Pink Sheet
unqualified) pursuant to Rule 15c2- 1 1 of the Securities Exchange Act of 1934.

Because our common stock is classified as "penny stock", trading is limited and
the common stock price declined to virtually no value and therefore is very
difficult to sell.

Because our common stock falls under the definition of "penny stock", the
trading in our common stock is limited because broker-dealers are required to
provide their customers with disclosure documents prior to allowing them to
participate in transactions involving our common stock.

We do not anticipate paying dividends.

We have not paid any cash dividend on our common stock since our inception and
we do not anticipate paying cash dividends in the foreseeable future and since
2001 we have not paid any dividends to the holders of the Company's preferred
stocks.

One of our current stockholders has significant influence over our management
and directors and may take actions that may not be in the best interest of other
stockholders.

Our co-founder beneficially owns approximately 66% of our common stock.
Therefore, he will be able, among other things, to elect directors.

We filed Chapter 11

We filed for protection under Chapter 11 in the United States Bankruptcy Court
for the District of Colorado.

Results of Operations

Three Months Ended May 31, 2007 as Compared to Three Months Ended May 31, 2006.

We had $3,129 in revenues for the Three Months Ended May 31, 2007 ("First
Quarter Ended Fiscal 2008") and no revenues for the Three Months Ended May 31,
2007 ("First Quarter Ended Fiscal 2007") due to the Company divesting
substantially all of its assets and as a result ceased operations on May 2,
2002. The increase in revenues is attributed to the Company generating sales
commissions relating to its appointment of being an exclusive independent sales
representative for certain medical and disposable product lines.



                                       15
<PAGE>

Selling, general and administrative ("SG&A") expenses for the First Quarter
Ended Fiscal 2008 were $8,683, an increase of $5,199 as compared to $3,484 in
expenses for the First Quarter Ended Fiscal 2007. The increase in SG&A expenses
for the First Quarter Ended Fiscal 2008 is attributed to our legal and account
fees, interest and other related administrative obligations.

Total Other Expense for the First Quarter Ended Fiscal 2008 were $6,954, an
increase of $1,277 as compared to $5,677 for First Quarter Ended Fiscal 2007.
The Total Other Expense increase is attributed to additional interest expenses
relating to Notes Payables and Credit Facility and other related administrative
obligations.

As a result of the foregoing, the net loss for the First Quarter Ended Fiscal
2008 was $22,507 an increase of $8,690 as compared to net loss of $13,817 for
the First Quarter Ended Fiscal 2007. The net loss for the First Quarter Ended
Fiscal 2008 is attributed to increases in legal and accounting fees, interest
and other related administrative obligations.

Liquidity and Capital Resources

Since inception, we have been undercapitalized and have experienced financial
difficulties. Our primary sources of working capital have been revenues from
operations, bank and private party loans and proceeds from the sale of
securities. Many of the bank and private party loans and certain of our other
obligations have required personal guarantees in order to continue to operate
our business. In May 2002, the Company divested substantially all of its assets
and ceased operations, and has performed only administrative duties as a
transitory, or shell, corporation. On September 2006, the Company re-entered the
medical device industry by being appointed as an exclusive independent sales
representative for certain surgical instruments and disposable devices. As of
May 31, 2007, the Company continued to generate revenues from the sales
commissions. Our working capital at May 31, 2007 was negative in deficit.

On June 15, 2002, and March 2004, we issued various Convertible Secured Notes
(the "Notes") to LKDTBJP Living Trust, (the "Living Trust") in the aggregate
amount of $380,286 for assuming certain of our trade and notes payable
obligations. The terms of the Notes are that both of the principal and accrued
interest are due on February 28, 2008. The Notes carry a 6% interest per annum.
At the option of Living Trust, he Notes are convertible at any time into
15,000,000 shares of the Company's Common Stock. The value of these shares are
approximately $1,500.

In September 5, 2005, the Company entered into a Revolving Credit Facility
Agreement (the"Agreement"), by and between Gary A Agron and LKDTBJP Living
Trust, (collectively (the "Lender"). This Agreement allows the Company to borrow
up to $100,000 with interest charged at 6.0% per annum, and both principal and
accrued interest is due on February 28, 2008. The Company further agreed not to
issue any additional equity or any other type of security without the written
consent of the Lender. In consideration of the Lender providing this Agreement,


                                       16
<PAGE>

the Company has agreed to issue each of Agron and LKDTBJP Living Trust
46,269,023 shares of its Common Stock. On October 6, 2006, subject to the
confirmation of the Company's Plan of Reorganization, the Agreement was amended
to issue a total of 10,000,000 shares of its Common Stock to the Lender. The
value of these shares is approximately $1,000.

Item 3. Controls and Procedures

The Company maintains controls and procedures designed to ensure that the
information required to be disclosed in the reports that the Company files or
submits under the Securities Exchange Act of 1934, is recorded, processed,
summarized and reported within the time periods specified in the rules and forms
of the Securities Exchange Commission. Based upon their evaluation of those
controls and procedures performed within 90 days of the filing date of this
report, the Company's chief executive officer and the principal financial
officer (or persons performing similar functions) concluded that the Company's
disclosure controls and procedures were adequate.

As a result of its evaluation, the Company has been made no significant changes
in its internal controls or other factors that could significantly affect the
controls and other procedures already in place.

Part II. Other Information

Item 1. Legal Proceedings.

On November 6, 2006, the Company filed its Voluntary Petition under Chapter 11
of the Title 1 of the United States Code Bankruptcy for District of Colorado
under Case#06-18117-ABC. On this petition date, the Company its Proposed Plan of
Reorganization and accompanying Disclosure Statement ("the Plan"). As of
November 9, 2007, the United States Bankruptcy Court for the District of
Colorado has not yet ruled on the confirmation of such Plan.

Item 2. Changes in Securities

None.



                                       17
<PAGE>

Item 3. Default Upon Senior Securities.

None.

Item 4. Submission of Matters to a Vote of Security Holders.

None.

Item 5. Other Information

None.

Item 6. Exhibits and Reports on Form 8-K

a) Exhibits

Number            Description
------            ------------

31.1              Certification by Chief Executive and Chief Financial Officer
                  pursuant to Sarbanes-Oxley Section 302.

32.1              Certification by Chief Executive and Chief Financial Officer
                  pursuant to 18 U.S.C. Section 1350.

b) Reports on Form 8K

None


SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.

Sparta Surgical Corporation
        (Registrant)
Date: November 9, 2007                        By: /s/ Allan J. Korn
                                              ---------------------------
                                              Allan J. Korn
                                              Chief Executive Officer and
                                              Chief Financial Officer



                                       18

--------------------------------------------------------------------------------